Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 6/20 | 0.33 |
| ▸ | BTK | Q06187 | 4/20 | 0.32 |
| ▸ | JAK2 | O60674 | 3/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | TTK | P33981 | 2/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.31 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13623303 | 0.91 | BCL6 (0.36) | BCL6F11JAK3AURKAEGFR | |
| SCHEMBL1076060 | 0.88 | BCL6 (0.35) | BCL6F11 | |
| SCHEMBL4359430 | 0.83 | NPC1 (0.36) | F11AURKAPTGER3MAPT | |
| SCHEMBL4365344 | 0.81 | BCL6 (0.38) | BCL6JAK3AURKA | |
| SCHEMBL13623299 | 0.79 | BCL6 (0.37) | BCL6JAK3BTKAURKA | |
| SCHEMBL13670011 | 0.77 | BCL6 (0.37) | BCL6 | |
| SCHEMBL4485009 | 0.75 | BCL6 (0.36) | BCL6JAK3AURKA | |
| SCHEMBL13623302 | 0.74 | TLR7 (0.38) | F11AURKAMAPT | |
| SCHEMBL4335022 | 0.71 | BTK (0.42) | JAK3BTKEGFR | |
| SCHEMBL1026903 | 0.70 | STK17B (0.41) | BCL6BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | BCL6 392/4885F11 3082/4885JAK3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.